Sci Rep

Oral vs. transdermal menopausal hormone therapy: What's the effect on NAFLD?

September 27, 2023

Findings indicate that transdermal estrogen is more beneficial than oral estrogen in terms of preventing the progression or development of NAFLD in postmenopausal women.

• This study included 368 postmenopausal women who received MHT for one year. Based on the route of estrogen, patients were divided into transdermal (n = 75) and oral (n = 293) groups.
• After MHT, NAFLD prevalence decreased from 24% to 17.3% in the transdermal group but increased from 25.3% to 29.4% in the oral group.
• Changes in the prevalence of NAFLD weren't significantly different based on the dose of estrogen or type of progestogen.

Source:

Kim S.E., et al. (2023, September 19). Sci Rep. Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509271/